Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $7.33M rose 250.7% year over year, ahead of the +179.5% change in trailing-twelve-month free cash flow. Over 3 fiscal years it compounded at +71.1% a year.
Context
- Free cash flow amounted to 12.7% of revenue in FY2025, up 10.3 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +250.7% holds above the trailing-twelve-month pace of +179.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 10.19M USD
- Year-over-year change
- +980.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.19M | +980.7% |
| FY2024 | 2024-12-31 | 943K | -84.4% |
| FY2023 | 2023-12-31 | 6.04M | +197.1% |
| FY2022 | 2022-12-31 | 2.03M | +125.5% |
| FY2021 | 2021-12-31 | (7.98M) | — |
Free Cash Flow vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 free cash flow of $15.43M is the 8th largest of the 10 companies compared; the peer median is $31.09M.
- Its year-over-year change of +179.5% is the 3rd highest of 10, against a peer median of +50.2%.
- Free cash flow amounts to 17.8% of revenue for ETON, versus a peer median of 20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $616.26M | +103.6% | +2.8% | 64.2% | |
| LTM Mar 2026 | $487.2M | +18.0% | -3.6% | 72.8% | |
| LTM Sep 2026 | $134.22M | +267.1% | -54.4% | 20.6% | |
| LTM Mar 2026 | $131.32M | +50.2% | +60.0% | — | |
| LTM Mar 2026 | $50.07M | +883.5% | +34.0% | 13.6% | |
| LTM Mar 2026 | $38.8M | -77.0% | -9.0% | 55.7% | |
| LTM Mar 2026 | $31.09M | +37.5% | +35.9% | — | |
| LTM Mar 2026 | $15.43M | +179.5% | +71.1% | 17.8% | |
| LTM Mar 2026 | $12M | +119.4% | -49.4% | 9.8% | |
| LTM Mar 2026 | $5.78M | -64.7% | -11.6% | 11.3% | |
| Peer median (excluding ETON) | $31.09M | +50.2% | -3.6% | 20.6% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| Deferred Income Tax | (546K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.38M | 4.22M | 3.14M | 3.17M | 5.51M |
| Change in Working Capital | (6.21M) | 7.66M | 3.53M | (698K) | (859K) |
| Accounts Receivables | (5.42M) | 3.62M | (1.56M) | (3.12M) | (6.4M) |
| Inventory | 692K | (7K) | (354K) | (1.31M) | (5.88M) |
| Accounts Payables | (570K) | (8K) | 53K | 2.32M | 6.81M |
| Other Working Capital | (910K) | 4.06M | 5.39M | 1.41M | 4.61M |
| Other Non-Cash Items | 148K | 189K | 184K | 1.18M | 6.43M |
| Operating Cash Flow | (4.72M) | 4.82M | 6.82M | 969K | 10.52M |
| Capital Expenditures | (3.26M) | (2.79M) | (775K) | (26K) | (333K) |
| Acquisitions (Net) | 700K | 0 | 0 | (30M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (2.75M) | 0 | (9.99M) | 0 |
| Investing Cash Flow | (2.56M) | (2.79M) | (775K) | (40.01M) | (333K) |
| Debt Repayment | (150K) | (385K) | (1.16M) | 24.15M | 0 |
| Common Stock Issued | 541K | 0 | 0 | 8.19M | 598K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 251K | 198K | 248K | 217K |
| Financing Cash Flow | 391K | (134K) | (957K) | 32.59M | 815K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.89M) | 1.9M | 5.08M | (6.45M) | 11.01M |
| Free Cash Flow | (7.98M) | 2.03M | 6.04M | 943K | 10.19M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.